Merck KGaA and London-based Avillion have signed an agreement to collaborate on the development of the

To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever.

Avillion LLPBiotechnologyDealsGermanyImmunologicalsLicensingMerck KGaAUK

Access The Pharma Letter's latest news free for 7 days

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Click here to take a free trial

Unlimited access to The Pharma Letter site for a whole year Only 77 per month or 820 per year

Click here to subscribe

Here is the original post:
Following industry trend, Merck offloads mid-stage immunology candidate - The Pharma Letter (registration)